In an international multicenter randomized phase 3 clinical trial led by Dana-Farber Cancer Institute, researchers tested the addition of the immune checkpoint inhibitor (ICI) nivolumab to treatment with tivozanib for patients with advanced clear cell renal cell carcinoma, a form of kidney cancer.
Dana-Farber Cancer InstituteSep 13 2024 Study title: Tivozanib Plus Nivolumab vs Tivozanib Monotherapy in Patients with Renal Cell Carcinoma Following an Immune Checkpoint Inhibitor – Results of the Phase 3 TiNivo-2 StudyDana-Farber Cancer Institute authors: Toni K. Choueiri, MD, Bradley McGregor, MD
Summary: In an international multicenter randomized phase 3 clinical trial led by Dana-Farber Cancer Institute, researchers tested the addition of the immune checkpoint inhibitor nivolumab to treatment with tivozanib for patients with advanced clear cell renal cell carcinoma, a form of kidney cancer. Tivozanib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, has antiangiogenic effects and is thought to be synergistic with an ICI.
Related StoriesSignificance: Immune checkpoint inhibitors such as those that block PD-1 and PD-L1 have revolutionized cancer therapy and become part of standard first-line therapy for many solid tumors, including for advanced kidney cancer. Questions remain about how best to sequence treatment with an ICI after progression on prior ICI. This study is only the second to ask such a question. Repeat ICI therapy should be discouraged in patients with advanced renal cell carcinoma.
Kidney Kidney Cancer Carcinoma Cell Clinical Trial Renal Cell Carcinoma
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Experimental mRNA cancer vaccine shows potential for advanced stage cancer patients in Phase I trialInterim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers.
Read more »
New trial explores BAFF CAR T-cell therapy for relapsed myelomaUniversity Hospitals (UH) Seidman Cancer Center hematologist-oncologist Leland Metheny, MD, is leading the trial.
Read more »
Promising lung cancer vaccine trial starts in UKThe jab given to 67-year-old Janusz Racz may revolutionise how this cancer is treated, say doctors.
Read more »
Cancer fighting jab showing early promise in trialsA vaccine designed to fight cancer cells has shown promising signs in an early trial.
Read more »
‘Finally there is hope on the horizon’ – excitement over pancreatic cancer jab in BirminghamPancreatic cancer is one of the most deadly forms of cancer.
Read more »
Computational tool reveals untapped efficacy of cancer drug, leveling up cancer fightResearch from Purdue University in collaboration with the National Institutes of Health (NIH) reveals that, thanks to a new computational tool, a cancer drug dismissed by traditional testing methods may be effective in treating bladder cancer.
Read more »